Sun Pharma's Strategic Leap: Acquires Organon for $11.75 Billion

Sun Pharmaceutical Industries Ltd is set to acquire US-based Organon & Co in an all-cash deal valued at $11.75 billion. This acquisition positions Sun Pharma among the top 25 global pharmaceutical firms, enhancing its brand and product diversity. The transaction awaits regulatory approvals and stockholder endorsement.

Sun Pharmaceutical Industries Ltd has announced its acquisition of US-based Organon & Co in an all-cash transaction valued at an enterprise worth of $11.75 billion.

The agreement positions Sun Pharma among the world's top 25 pharmaceutical companies, bolstering its brand and product range. With this deal, Sun Pharma's vision of 'reaching people and touching lives' sees significant advancement.

The acquisition is expected to strengthen Sun Pharma's position in global women's health and biosimilars, expanding its presence to 150 countries with substantial revenue gains anticipated upon formal completion, pending regulatory and shareholder approvals.